---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000032"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:28:51.114221+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors

## Summary
- FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.
- First LockBody candidate to enter clinic; designed to activate CD47 in tumor microenvironment avoiding systemic toxicity.
- CEO Saurabh Saha calls it an important milestone; company plans to advance multiple LockBody candidates.
- Phase 1/2a first-in-human trial initiation expected as soon as possible.

## SEC filing metadata
- accession: 0001847903-23-000032
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/0001847903-23-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/cnta-20230126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000032
- JSON: https://secwatch.observer/filing/0001847903-23-000032.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.